Warts Therapeutics Market Report 2026

The warts therapeutics market size has grown steadily in recent years. It will grow from $2.01 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to limited awareness of hpv prevention, reliance on conventional chemical treatments, high incidence of common and plantar warts, slow adoption of immunotherapy, fragmented dermatology care systems.

The warts therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.48 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to advances in biologics and immunomodulators, rising awareness about hpv vaccination, growth in homecare treatment solutions, increasing dermatology clinical trials, expansion of dermatology-focused healthcare infrastructure. Major trends in the forecast period include rising prevalence of hpv-related skin disorders, development of topical and targeted therapeutics, increased focus on pediatric dermatology, expansion of homecare and otc wart treatments, growing adoption of combination therapies.

The increasing accessibility to healthcare services is expected to drive the growth of the wart therapeutics market in the coming years. Healthcare services involve the delivery of medical care, treatment, and support to individuals to maintain or improve their health. Wart therapeutics are used to treat common skin conditions caused by the human papillomavirus (HPV), helping alleviate symptoms, promote healing, and prevent the spread of warts, thereby supporting overall patient well-being. For instance, in April 2025, the Office for National Statistics, a UK-based organization, reported that nominal UK healthcare expenditure reached approximately $414.03 billion (£317 billion) in 2024, a 6.5% increase from 2023. Consequently, the rise in healthcare accessibility is fueling the growth of the wart therapeutics market.

Leading companies in the wart therapeutics market are leveraging strategic partnerships to advance clinical research and develop new therapies. Strategic partnerships enable companies to combine expertise, resources, and capabilities to achieve shared goals. For example, in June 2023, Vial, a US-based pharmaceuticals company, partnered with Nielsen BioSciences Inc., also US-based, to study the safety and efficacy of CANDIN, a diagnostic skin test for common warts, supporting the development of innovative treatments for patients and sponsors.

In July 2025, Verrica Pharmaceuticals, a US-based provider of dermatology therapeutics, collaborated with Torii Pharmaceutical Co. Ltd., a Japan-based pharmaceutical manufacturer, to co-fund and conduct a global phase 3 clinical trial of YCANTH (VP-102) for common warts. This partnership expands Verrica’s presence in the wart therapeutics market while strengthening its dermatology product portfolio.

Major companies operating in the warts therapeutics market are GlaxoSmithKline plc, Merck & Co. Inc., Verrica Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd, Cipla Inc., Maruho Co. Ltd, Taro Pharmaceutical Industries Ltd, Aclaris Therapeutics Inc., Compound W, Duofilm, MedCara Pharmaceuticals, Novan Inc, Prestige Consumer Healthcare Inc., KinoPharma Inc., Phio Pharmaceuticals Corp., Emblation Ltd., Meda Pharmaceuticals, Dermira Inc., Celgene Corporation, Akorn Pharmaceuticals, Biofrontera AG, Medicis Pharmaceutical Corporation.

North America was the largest region in the warts therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warts therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the warts therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the warts therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs), medical devices, and topical formulations, leading to higher production costs. The chemical destruction and immunomodulation segments are most affected, especially in regions dependent on imports such as North America and Europe. While tariffs pose cost challenges, they have also encouraged local manufacturing and sourcing of raw materials, potentially accelerating domestic innovation and improving supply chain resilience.

The warts therapeutics market research report is one of a series of new reports that provides warts therapeutics market statistics, including warts therapeutics industry global market size, regional shares, competitors with a warts therapeutics market share, detailed warts therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the warts therapeutics industry. This warts therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Warts therapeutics refer to medications used to treat warts, a skin condition caused by the human papillomavirus (HPV). These treatments are applied to manage warts occurring on various parts of the body, including the hands, face, and feet.

The main types of warts in warts therapeutics include common warts, genital warts, flat warts, and others. Common warts are small, rough skin growths that usually appear on the hands or fingers. Treatments involve physical removal, immunomodulation, and chemical destruction. Warts therapeutics are used in hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The warts therapeutics market consists of sales of therapeutic drugs such as 5-fluorouracil, benzalkonium, glutaraldehyde, cryotherapy, or podophyllin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.